102 related articles for article (PubMed ID: 15476674)
1. A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug.
Wang Y; Minko T
Biochem Pharmacol; 2004 Nov; 68(10):2031-42. PubMed ID: 15476674
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.
Pakunlu RI; Wang Y; Tsao W; Pozharov V; Cook TJ; Minko T
Cancer Res; 2004 Sep; 64(17):6214-24. PubMed ID: 15342407
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin.
Pakunlu RI; Cook TJ; Minko T
Pharm Res; 2003 Mar; 20(3):351-9. PubMed ID: 12669953
[TBL] [Abstract][Full Text] [Related]
4. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor.
Wang Y; Saad M; Pakunlu RI; Khandare JJ; Garbuzenko OB; Vetcher AA; Soldatenkov VA; Pozharov VP; Minko T
Clin Cancer Res; 2008 Jun; 14(11):3607-16. PubMed ID: 18519795
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
Pakunlu RI; Wang Y; Saad M; Khandare JJ; Starovoytov V; Minko T
J Control Release; 2006 Aug; 114(2):153-62. PubMed ID: 16889867
[TBL] [Abstract][Full Text] [Related]
6. Bimodal effect of hypoxia in cancer: role of hypoxia inducible factor in apoptosis.
Wang Y; Pakunlu RI; Tsao W; Pozharov V; Minko T
Mol Pharm; 2004; 1(2):156-65. PubMed ID: 15832512
[TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
9. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
10. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
[TBL] [Abstract][Full Text] [Related]
11. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
Lo YL; Liu Y
PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
[TBL] [Abstract][Full Text] [Related]
12. JNK1 as a molecular target to limit cellular mortality under hypoxia.
Betigeri S; Pakunlu RI; Wang Y; Khandare JJ; Minko T
Mol Pharm; 2006; 3(4):424-30. PubMed ID: 16889436
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-Functionalized DNA Origami for Targeted Codelivery of Antisense Oligonucleotides and Doxorubicin to Enhance Therapy in Drug-Resistant Cancer Cells.
Pan Q; Nie C; Hu Y; Yi J; Liu C; Zhang J; He M; He M; Chen T; Chu X
ACS Appl Mater Interfaces; 2020 Jan; 12(1):400-409. PubMed ID: 31815420
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
15. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas.
Zhang Q; Zhang ZF; Rao JY; Sato JD; Brown J; Messadi DV; Le AD
Int J Cancer; 2004 Oct; 111(6):849-57. PubMed ID: 15300796
[TBL] [Abstract][Full Text] [Related]
16. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
18. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
19. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.
Mainelis G; Seshadri S; Garbuzenko OB; Han T; Wang Z; Minko T
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):345-54. PubMed ID: 23530772
[TBL] [Abstract][Full Text] [Related]
20. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]